NCT06577519 Efficacy and Safety Study of Vicagrel in Patients With Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)
| NCT ID | NCT06577519 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Jiangsu vcare pharmaceutical technology co., LTD |
| Condition | Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI) |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2024-09-06 |
| Primary Completion | 2026-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 1,000 participants in total. It began in 2024-09-06 with a primary completion date of 2026-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a multi-center, randomized, double-blind, double-dummy, parallel-controled, phase III trial, aiming to evaluate the effectiveness and safety of long-term continuous administration of Vicagrel capsules in ACS patients undergoing PCI.
Eligibility Criteria
Inclusion Criteria: * Patients between 18 and 80 years old, with no gender restrictions. * Patients diagnosed with ACS and scheduled for PCI, including STEMI and NSTE-ACS (UA/NSTEMI). * Voluntarily sign the ICF and be able to follow the visit arrangements specified in the protocol during the trial period. Exclusion Criteria: * Expected survival time\<12 months; * Severe liver dysfunction (non heart disease induced ALT or AST\>3x ULN) and cirrhosis; * Pregnant or lactating women, or participants and their partners who plan to become pregnant during the trial period; * The researchers determined that other reasons were not suitable for participants in this experiment.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06577519 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06577519 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 1,000 participants.
Is NCT06577519 currently recruiting?
Yes, NCT06577519 is actively recruiting participants. Contact the research team at lai_xiaojuan@vcarepharmatech.com for enrollment information.
Where is the NCT06577519 trial being conducted?
This trial is being conducted at Shenyang, China.
Who is sponsoring the NCT06577519 clinical trial?
NCT06577519 is sponsored by Jiangsu vcare pharmaceutical technology co., LTD. The trial plans to enroll 1,000 participants.